Medical Treatment of Cushing’s Syndrome: Adrenal-Blocking Drugs and Ketaconazole
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Cushing’s syndrome is associated with serious morbidity and increased mortality. Irrespective of its cause, i.e. a pituitary adenoma, ectopic ACTH production or an adrenal neoplasia, Cushing’s syndrome is primarily treated surgically. However, when surgery is unsuccessful or contraindicated, medical therapy is needed to treat hypercortisolism. The spectrum of available drugs includes adrenal-blocking agents, neuromodulatory drugs and glucocorticoid receptor antagonists. Adrenal blocking drugs suppress adrenal cortisol production via inhibition of steroidogenic enzymes. Ketoconazole and metyrapone are most frequently used for this purpose, but chronic treatment with these drugs can be limited by side effects like hepatotoxicity (ketoconazole) and increased androgen and mineralocorticoid production (metyrapone). Etomidate can be used to rapidly reverse cortisol excess in patients with acute complications of (severe) hypercortisolism like psychosis. In Cushing’s disease, combination therapy with drugs that target the corticotropic adenoma, i.e. the universal somatostatin analogue pasireotide and/or the dopamine agonist cabergoline, and low-dose ketoconazole seems a rational approach to achieve biochemical control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationTreatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853 · cited 1×
“Cushing’s syndrome (CS) is traditionally divided into adrenocorticotropin (ACTH)-dependent CS and ACTH-independent CS. ACTH-dependent CS is usually caused by a corticotropic pituitary adenoma and rarely by ectopic ACTH production by a neuroendocrine tumor. ACTH-independent CS is caused by an adrenal adenoma, adrenal c…”
BackgroundSelf-citationThe use of ketoconazole as an inhibitor of steroid production
Oates, J. A., Wood, A. J. J., & Sonino, N. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709243171307 · Cited by 395
Verhelst, J. A., Trainer, P. J., Howlett, T. A., Perry, L., Rees, L. H., Grossman, A. B., Wass, J. A. H., & Sesser, G. M. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03517.x · Cited by 308 · cited 1×
“and can decrease cortisol production in patients with adrenal tumors, ectopic ACTH production and Cushing’s disease [”
BackgroundKetoconazole treatment in Cushing’s syndrome: experience in 34 patients
Sonino, N., Boscaro, M., Paoletta, A., Mantero, F., & Zillotto, D. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03547.x · Cited by 201
Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease
Castinetti, F., Morange, I., Jaquet, P., Conte-Devolx, B., & Brue, T. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0514 · Cited by 175
Cited by
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Jensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J.-Y., Salazar, R., Sauvanet, A., & Kianmanesh, R. (2012) · Neuroendocrinology · doi:10.1159/000335591 · Cited by 622
Self-citationThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study
Dekkers, O. M., Horváth-Puhó, E., Jørgensen, J. O. L., Cannegieter, S. C., Ehrenstein, V., Vandenbroucke, J. P., Pereira, A. M., & Sørensen, H. T. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3582 · Cited by 419
Ketoconazole in Cushing's disease: is it worth a try?
Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Caron, P., Luca, F., Donadille, B., Vantyghem, M. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3628 · Cited by 285
Metadata
- Authors
- Feelders, R. A., Hofland, L. J., & de Herder, W. W.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 92
- Issue
- Suppl. 1
- Pages
- 111-115
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2110143379
- Cited by
- 94
- References
- 6
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medical Treatment of Cushing’s Syndrome: Adrenal-Blocking Drugs and Ketaconazole. https://app.cochat.ai/papers/10.1159/000314292
- The paper
- Feelders, R. A., Hofland, L. J., & de Herder, W. W. (2010). Medical Treatment of Cushing’s Syndrome: Adrenal-Blocking Drugs and Ketaconazole. Neuroendocrinology. https://doi.org/10.1159/000314292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.